Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.4.4 (
adenosine deaminase
)
5,136
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CD26 has proved interesting in the fields of immunology, endocrinology, cancer biology and nutrition owing to its ubiquitous and unusual enzyme activity. This dipeptidyl aminopeptidase (DPP IV) activity generally inactivates but sometimes alters or enhances the biological activities of its peptide substrates, which include several chemokines. CD26 costimulates both the CD3 and the CD2 dependent T-cell activation and tyrosine phosphorylation of TCR/CD3 signal transduction pathway proteins. CD26 in vivo has
integral membrane protein
and soluble forms. Soluble CD26 is at significant levels in serum, these levels alter in many diseases and soluble CD26 can modulate in vitro T-cell proliferation. CD26, being an
adenosine deaminase
binding protein (ADAbp), functions as a receptor for ADA on lymphocytes. The focus of this review is the structure and function of CD26 and the influence of its ligand binding activity on T-cell proliferation and the T cell costimulatory activity of CD26.
...
PMID:CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. 1155 88
The extra-enzymic function of cell-surface
adenosine deaminase
(
ADA
), an enzyme mainly localized in the cytosol but also found on the cell surface of monocytes, B cells and T cells, has lately been the subject of numerous studies. Cell-surface
ADA
is able to transduce co-stimulatory signals in T cells via its interaction with CD26, an
integral membrane protein
that acts as
ADA
-binding protein. The aim of the present study was to explore whether
ADA
-CD26 interaction plays a role in the adhesion of lymphocyte cells to human epithelial cells. To meet this aim, different lymphocyte cell lines (Jurkat and CEM T) expressing endogenous, or overexpressing human, CD26 protein were tested in adhesion assays to monolayers of colon adenocarcinoma human epithelial cells, Caco-2, which express high levels of cell-surface
ADA
. Interestingly, the adhesion of Jurkat and CEM T cells to a monolayer of Caco-2 cells was greatly dependent on CD26. An increase by 50% in the cell-to-cell adhesion was found in cells containing higher levels of CD26. Incubation with an anti-CD26 antibody raised against the
ADA
-binding site or with exogenous
ADA
resulted in a significant reduction (50-70%) of T-cell adhesion to monolayers of epithelial cells. The role of
ADA
-CD26 interaction in the lymphocyte-epithelial cell adhesion appears to be mediated by CD26 molecules that are not interacting with endogenous
ADA
(
ADA
-free CD26), since SKW6.4 (B cells) that express more cell-surface
ADA
showed lower adhesion than T cells. Adhesion stimulated by CD26 and
ADA
is mediated by T cell lymphocyte function-associated antigen. A role for
ADA
-CD26 interaction in cell-to-cell adhesion was confirmed further in integrin activation assays. FACS analysis revealed a higher expression of activated integrins on T cell lines in the presence of increasing amounts of exogenous
ADA
. Taken together, these results suggest that the
ADA
-CD26 interaction on the cell surface has a role in lymphocyte-epithelial cell adhesion.
...
PMID:Regulation of epithelial and lymphocyte cell adhesion by adenosine deaminase-CD26 interaction. 1177 92